



Neglected giant benign phyllode tumor of the breast

Marc-Antoine Benderra¹ · Clement Ferrier² · David Buob³ · Joseph Gligorov^{1,4} · Khaldoun Kerrou^{4,5}

Received: 8 April 2022 / Accepted: 9 May 2022 / Published online: 18 May 2022


© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abbreviations

APT Adjuvant paclitaxel trastuzumab

A 51-year-old woman presented herself to the gynecology unit with an increase in volume of the right breast that

appeared more than a year earlier. The ulcerating mass measured more than 30 cm. The patient was delayed in consulting due to the COVID-19 pandemic. On admission, she had an Eastern Cooperative Oncology Group performance-status (ECOG-PS) score of 4, albuminemia at 8 g/dl with a high level of C-reactive protein. ¹⁸F-FDG PET/CT was performed



This article is part of the Topical Collection on Image of the month

✉ Marc-Antoine Benderra
marc-antoine.benderra@aphp.fr

¹ Institut Universitaire de Cancérologie, Sorbonne University, AP-HP, Tenon Hospital, Department of Medical Oncology, Paris, France

² Sorbonne University, APHP, Tenon Hospital, Department of Gynaecology and Obstetrics, Paris, France

³ Sorbonne University, APHP, Tenon Hospital, Department of Pathology, Paris, France

⁴ Team Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Inserm UMR_S 938, Paris, France

⁵ Institut Universitaire de Cancérologie, Sorbonne University, AP-HP, Tenon Hospital, Department of Nuclear Medicine and PET Center, Paris, France

for staging a suspected malignant breast cancer. The maximum standardized uptake value (SUV_{max}) measured in the right breast tumor was 7.4 (volume-rendering images of ¹⁸F-FDG PET (A), CT (B), and fused PET/CT (C)). The pathologic examinations of the biopsies were benign. In the other breast, the ¹⁸F-FDG PET identified a 23-mm lesion whose biopsy found an invasive carcinoma ER-positive/Her2-positive. Although the anesthetic risk was high, it was decided to perform the surgery. A right mastectomy and left breast conservative surgery with sentinel-lymph-node resection were performed in the same time. The final pathologic examination confirmed a benign phyllode tumor of 36 cm on the right breast and an invasive Her2-positive breast cancer on the left. For the left breast, radiotherapy and adjuvant chemotherapy with APT [1] were performed

then endocrine therapy. After the surgery, the patient quickly recovered an ECOG-PS of 0. This case highlights the fact that surgery remains the standard treatment for low-grade phyllode tumors.

Declarations

Ethics approval and informed consent All procedures performed involving the human participant were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patient.

Competing interests The authors declare no competing interests.

Reference

1. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 1 août. 2019;37(22):1868–75.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.